Drug Overview
Lynparza (olaparib; AstraZeneca/Merck & Co) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of BRCA mutation-positive (BRCAm+) ovarian cancer. The PARP enzyme plays an essential role in DNA repair mechanisms and homologous recombination events. PARP inhibitors act by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death. Tumor cells with BRCA1/2 gene mutations are dependent on PARP for DNA damage repair, and PARP inhibition selectively kills BRCA1- or BRCA2-deficient cells. As DNA repair is inhibited by PARP inhibitors, they are often sequenced after a cytotoxic chemotherapy which works by damaging DNA.
BRCA1 and BRCA2 encode proteins that are required for DNA damage repair. Inherited mutations in these genes have been linked to a predisposition towards the development of breast and ovarian cancers. In the US, it has been estimated that inherited BRCA1 and BRCA2 mutations account for 5-10% of breast cancers and 10-15% of ovarian cancers among white women.
The drug is also being developed by AstraZeneca and Merck & Co for the treatment of prostate cancer.
Lynparza (olaparib; AstraZeneca/Merck & Co) is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor for the treatment of BRCA mutation-positive (BRCAm+) ovarian cancer. The PARP enzyme plays an essential role in DNA repair mechanisms and homologous recombination events. PARP inhibitors act by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death. Tumor cells with BRCA1/2 gene mutations are dependent on PARP for DNA damage repair, and PARP inhibition selectively kills BRCA1- or BRCA2-deficient cells. As DNA repair is inhibited by PARP inhibitors, they are often sequenced after a cytotoxic chemotherapy which works by damaging DNA.
BRCA1 and BRCA2 encode proteins that are required for DNA damage repair. Inherited mutations in these genes have been linked to a predisposition towards the development of breast and ovarian cancers. In the US, it has been estimated that inherited BRCA1 and BRCA2 mutations account for 5-10% of breast cancers and 10-15% of ovarian cancers among white women.
The drug is also being developed by AstraZeneca and Merck & Co for the treatment of prostate cancer.
Table of Contents
Product ProfilesLynparza: Prostate cancer
Lynparza: Ovarian cancer
Lynparza: Breast cancer: triple-negative
Lynparza: Pancreatic cancer
Lynparza: Breast cancer: HR+/HER2-
List of Figures
Figure 1: Lynparza for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of Lynparza for prostate cancer
Figure 3: Drug assessment summary of Lynparza for prostate cancer
Figure 4: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26
Figure 5: Lynparza for ovarian cancer - SWOT analysis
Figure 6: Drug assessment of Lynparza for ovarian cancer
Figure 7: Drug assessment of Lynparza for ovarian cancer
Figure 8: Lynparza for triple-negative breast cancer - SWOT analysis
Figure 9: Drug assessment summary of Lynparza for triple-negative breast cancer
Figure 10: Drug assessment summary of Lynparza for triple-negative breast cancer
Figure 11: Lynparza for pancreatic cancer - SWOT analysis
Figure 12: Drug assessment summary of Lynparza in pancreatic cancer
Figure 13: Drug assessment summary of Lynparza in pancreatic cancer
Figure 14: Lynparza for HR+/HER2- breast cancer - SWOT analysis
Figure 15: Drug assessment summary of Lynparza in HR+/HER2- breast cancer
Figure 16: Drug assessment summary of Lynparza in HR+/HER2- breast cancer
List of Tables
Table 1: Lynparza drug profile
Table 2: Lynparza Phase III trial in prostate cancer
Table 3: Lynparza Phase II data in prostate cancer
Table 4: Lynparza sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26
Table 5: Lynparza drug profile
Table 6: Lynparza pivotal trial data in ovarian cancer
Table 7: Lynparza ongoing late-phase clinical trials in ovarian cancer
Table 8: Overview of early-phase data for Lynparza in ovarian cancer
Table 9: Lynparza drug profile
Table 10: Lynparza Phase III trials in triple-negative breast cancer
Table 11: Lynparza Phase II data in triple-negative breast cancer
Table 12: Lynparza drug profile
Table 13: Lynparza Phase III trials in pancreatic cancer
Table 14: Lynparza drug profile
Table 15: Lynparza Phase III trial in HR+/HER2- breast cancer
Table 16: Lynparza Phase II data in HR+/HER2- breast cancer
